Skip to main content

News

New, Improved Therapy for Pompe Disease

Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more favorable safety profile compared to the current standard of care (alglucosidase alfa).

RheumNow Podcast – Combination Biologics

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Planes, Trains and COVID Distancing

MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy).

Autoimmune Risk of Death Up during COVID

A population-based study in the UK shows that patients with rare autoimmune rheumatic diseases (RAIRD) were 44% more likely to die during the 2020 COVID-19 pandemic (March - April) compared to either the general population or their pre-COVID risk.

USPSTF - No Need to Screen for Vitamin D Deficiency

JAMA has published the new recommendation from the US Preventive Services Task Force (USPSTF) stating that screening for vitamin D deficiency is unnecessary and unwarranted in asymptomatic adults.

NICE Guidelines on Chronic Pain Management

In the United Kingdom, where it is estimated that chronic pain affects one‑third to one‑half of the population, NICE (National Institute for Health and Care Excellence) has recently released an updated guideline on the management of chronic pain for people aged 16 years and over.

Sinusitis Activity Linked to Brain Dysfunction

Have you wondered why fibromyalgia, fatigue or cognitive dysfunction often co-associate with chronic sinusitis?

IL-23 Targeting for Enthesitis in Psoriatic Arthritis

MedPage Today

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.

Low Risk of Malignancy with Secukinumab

Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

DMARD Dropouts During COVID-19

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.

Anti-inflammatory Diet Control of Rheumatoid Arthritis

The TOMORROW study assessed the relationship between diet and disease activity in rheumatoid arthritis (RA) patients and has shown that RA patients are more likely to have higher inflammatory diets, but that a change to an anti-inflammatory diet resulted in lower disease activity s

RheumNow Podcast – Mistakes with Steroids

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
×